Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Yu Shyr, Kristen K. Ciombor, Gino Pineda, Yoanna Pumpalova, Chih-Yuan Hsu, Dana Backlund Cardin, Mehmet Asim Bilen, Laura W. Goff, Jordan Berlin, Ibrahim Halil Sahin, Shih Kai Chu, Christina Wu, Emily Pei Ying Lin, Satya Das, George A. Fisher, Sigurdis Haraldsdottir
Publikováno v:
Oncologist
Introduction Immune-related adverse event (IRAE) onset may represent a clinical biomarker for anti-programmed cell death protein 1 (PD-1) antibody response based on emerging evidence from patients with various advanced malignancies. This phenomenon h
Autor:
Wayne Harris, Lauren Yantorni, Jamie M. Goldman, Subir Goyal, Katherine Case, Sean Evans, Viraj A. Master, Greta Russler, Haydn T. Kissick, Bassel Nazha, T. Anders Olsen, Benjamin Magod, Yuan Liu, Mehmet Asim Bilen, Dylan J. Martini, Bradley C. Carthon, Omer Kucuk, Sarah Caulfield, Jacqueline T. Brown
Publikováno v:
Oncologist
Background Immune checkpoint inhibitors (ICIs) are an important treatment for metastatic renal cell carcinoma (mRCC). These agents may cause immune-related adverse events (irAEs), and the relationship between irAEs and outcomes is poorly understood.
Autor:
Christina Wu, Sigurdis Haraldsdottir, Chih-Yuan Hsu, Yu Shyr, Laura W. Goff, Ibrahim Halil Sahin, Emily Pei Ying Lin, Yoanna Pumpalova, Shih-Kai Chu, Jordan Berlin, Mehmet Asim Bilen, Kristen K. Ciombor, Dana Backlund Cardin, Satya Das
Publikováno v:
Journal of Clinical Oncology. 37:4116-4116
4116 Background: Despite the therapeutic promise of ICIs for patients (pts) with some advanced malignancies, they are FDA-approved for only a few GI cancer pts. In NSCLC, melanoma and urothelial carcinoma, there is emerging data that pts who experien
Autor:
Ronan Flippot, Nieves Martinez Chanza, John A. Steinharter, Bradley Alexander McGregor, Amin Nassar, Lauren C. Harshman, Ziad Bakouny, Mehmet Asim Bilen, Xiao X. Wei, Sarah Abou Alaiwi, Pier Vitale Nuzzo, Dylan J. Martini, Toni K. Choueiri, Wanling Xie
Publikováno v:
Journal of Clinical Oncology. 37:652-652
652 Background: CPI can induce a range of irAEs with various degrees of severity. Clinical experience with retreatment following clinically significant irAEs is growing. Methods: We retrospectively reviewed mRCC patients treated with CPI-based regime
Autor:
Sumit K. Subudhi, Padmanee Sharma, Jianjun Gao, Mehmet Asim Bilen, Nizar M. Tannir, Shi Ming Tu
Publikováno v:
Journal for Immunotherapy of Cancer
Background Immune checkpoint inhibitors have revolutionized cancer therapy since these drugs target inhibitory pathways on T cells, which result in durable anti-tumor immune responses and significant overall survival for a subset of cancer patients.